Maria-Luisa Maccecchini - 17 Nov 2023 Form 4 Insider Report for Annovis Bio, Inc. (ANVS)

Role
President and CEO, Director, 10%+ Owner
Signature
/s/ Maria Maccecchini
Issuer symbol
ANVS
Transactions as of
17 Nov 2023
Net transactions value
$0
Form type
4
Filing time
03 Jul 2024, 17:16:55 UTC
Previous filing
26 Apr 2023
Next filing
22 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANVS Common Stock Gift $0 -10,000 -0.91% $0.000000 1,088,459 28 Mar 2024 Direct F1
transaction ANVS Common Stock Gift $0 -10,000 -0.92% $0.000000 1,078,459 31 Mar 2024 Direct F1
transaction ANVS Common Stock Gift $0 -10,000 -0.93% $0.000000 1,068,459 31 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANVS Stock Option (right to buy) Award $0 +252,000 $0.000000 252,000 17 Nov 2023 Common Stock 252,000 $6.07 Direct F2, F3
transaction ANVS Stock Option (right to buy) Award $0 +108,800 $0.000000 108,800 17 Nov 2023 Common Stock 108,800 $6.07 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person.
F2 On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved.
F3 Stock option will vest in eight consecutive quarterly installments of 31,500 shares each on the 17th day of February, May, August and November of each year, continuing through November 17, 2025.
F4 The stock option was granted in lieu of cash payment for 2023 fiscal year bonus. 100% of the stock option grant listed was also contingent upon the aforementioned amendment to the 2019 Equity Incentive Plan to increase the number of issuable shares from 2,000,000 to 3,000,000. It would have been forfeited if the amendment had not been approved.
F5 The stock option shall vest immediately.